Phosphorylated p38MAPK specific antibodies cross-react with sarkosyl-insoluble hyperphosphorylated tau proteins

Journal of Neurochemistry

Volumn 90, Issue 4, 2004, Pages 829-838

  Sahara, Naruhiko ^b   Vega, Irving E ^a   Ishizawa, Takashi ^c   Lewis, Jada ^a   McGowan, Eileen ^a   Hutton, Michael ^a   Dickson, Dennis ^a   Yen, Shu Hui ^a  

^a MAYO GRADUATE SCHOOL   (United States)

^b RIKEN BRAIN SCIENCE INSTITUTE   (Japan)

^c SAITAMA MEDICAL UNIVERSITY   (Japan)

Author keywords

Active p38 mitogen activated protein kinase; Cross reactivity; Sarkosyl insoluble tau; Tauopathies

Indexed keywords

ANTIBODY; BRAIN EXTRACT; MITOGEN ACTIVATED PROTEIN KINASE P38; TAU PROTEIN;

ADULT; AGED; ALZHEIMER DISEASE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY LABELING; ARTICLE; CONTROLLED STUDY; CROSS REACTION; HUMAN; HUMAN TISSUE; IMMUNOPRECIPITATION; IMMUNOREACTIVITY; MOUSE; NEUROFIBRILLARY TANGLE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; SPINAL CORD; TAUOPATHY; TRANSGENIC MOUSE;

AGE FACTORS; ALZHEIMER DISEASE; ANIMALS; ANTIBODIES; ANTIBODY SPECIFICITY; BLOTTING, WESTERN; BRAIN; CROSS REACTIONS; DISEASE MODELS, ANIMAL; FEMALE; HUMANS; MICE; MICE, TRANSGENIC; MITOGEN-ACTIVATED PROTEIN KINASES; NEURONS; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PHOSPHORYLATION; PRECIPITIN TESTS; SARCOSINE; SOLUBILITY; SPINAL CORD; TAU PROTEINS; TAUOPATHIES;

ANIMALIA; MUS MUSCULUS;

EID: 4143121059     PISSN: 00223042     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1471-4159.2004.02558.x     Document Type: Article

References (55)

1. Allen B., Ingram E., Takao M. et al. (2002) Abundant tau filaments and nonapoptotic neurodegeneration in transgenic mice expressing human P301S tau protein. J. Neurosci. 2, 9340-9351.
2. Andorfer C., Kress Y., Espinoza M., DeSilva R., Tucker K. L., Barde Y.-A., Duff K. and Davies P. (2003) Hyperphosphorylation and aggregation of tau in mice expressing normal human tau isoforms. J. Neurochem. 86, 582-590.
3. Baum L., Hansen L., Masliah E. and Saitoh T. (1996) Glycogen synthase kinase 3 alteration in Alzheimer's disease is related to neurofibrillary tangle formation. Mol. Chem. Neuropathol. 29, 253-261.
4. Borghi R., Giliberto L., Assini A., Delacourte A., Perry G., Smith M. A., Strocchi P., Zaccheo D. and Tabaton M. (2002) Increase of cdk5 is related to neurofibrillary pathology in progressive supranuclear palsy. Neurology 58, 5895-5892.
5. Buee-Scherrer V. and Goedert M. (2002) Phosphorylation of microtubule-associated protein tau by stress-activated protein kinases in intact cells. FEBS Lett. 515, 151-154.
6. Chin J. Y., Knowles R. B., Schneider A., Drewes G., Mandelkow E. M. and Hyman B. T. (2000) Microtubule-affinity-regulating kinase (MARK) is tightly associated with neurofibrillary tangles in Alzheimer brain: a fluorescence resonance energy transfer study. J. Neuropathol. Exp. Neurol. 1, 966-971.
7. Cruz J. C., Tseng H.-C., Goldman J. A., Shih H. and Tsai L.-H. (2003) Aberrant Cdk5 Activation by p25 triggers pathological events leading to neurodegeneration and neurofibrillary tangles. Neuron 40, 471-483.
8. Dickson D. W., Kress Y., Crowe A. and Yen S.-H. (1985) Monoclonal antibodies to Alzheimer neurofibrillary tangles. 2. Demonstration of a common antigenic determinant between ANT and neurofibrillary degeneration in progressive supranuclear palsy. Am. J. Pathol. 120, 292-303.
9. Ferrer I., Blanco R., Carmona M. et al. (2001a) Phosphorylated map kinase (ERK1, ERK2) expression is associated with early tau deposition in neurons and glial cells, but not with increased nuclear DNA vulnerability and cell death, in Alzheimer's disease, Pick's disease, progressive supranuclear palsy, and corticobasal degeneration. Brain Pathol. 11, 144-158.
10. Ferrer I., Blanco R., Carmona M. and Puig B. (2001b) Phosphorylated mitogen-activated protein kinase (MAPK/ERK-P), protein kinase of 38 kDa (p38-P), stress-activated protein kinase (SAPK/JNK-P), and calcium/calmodulin-dependent kinase II (CaM kinase II) are differentially expressed in tau deposits in neurons and glial cells in tauopathies. J. Neural Transmission 108, 1397-1415.
11. Ferrer I., Barrachina M., Tolnay M., Rey M. J., Vidal N., Carmona M., Blanco R. and Puig B. (2003) Phosphorylated protein kinases associated with neuronal and glial tau deposits in argyrophilic grain disease. Brain Pathol. 13, 62-78.
12. Friedhoff P., Schneider A., Mandelkow E. M. and Mandelkow E. (1998) Rapid assembly of Alzheimer-like paired helical filaments from microtubule-associated protein tau monitored by fluorescence in solution. Biochemistry. 37, 10223-10230.
13. Ghoshal N., Garcia-Sierra F., Wuu J., Leurgans S., Bennet D. A., Berry R. W. and Binder L. I. (2002) Tau conformational changes correspond to impairments of episodic memory in mild cognitive impairment and Alzheimer's disease. Exp. Neurol. 177, 475-493.
14. Goedert M., Jakes R., Spillantini M., Hasegawa M., Smith M. J. and Crowther R. A. (1996) Assembly of microtubule-associated protein tau into Alzheimer-like filaments induced by sulphated glycosaminoglycans. Nature 383, 550-553.
15. Goedert M., Hasegawa M., Jakes R., Lawler S., Cuenda A. and and- Cohen P. (1997) Phosphorylation of microtubule-associated protein tau by stress-activated protein kinases. FEBS Lett. 409, 57-62.
16. Grundke-Iqbal I., Iqbal K., Quinlan M., Tung Y. C., Zaidi M. S. and Wisniewski H. M. (1986) Microtubule-associated protein tau. A component of Alzheimer paired helical filaments. J. Biol. Chem. 261, 6084-6089.
17. Hensley K., Floyd R. A., Zheng N.-Y. et al. (1999) p38 kinase is activated in the Alzheimer's disease brain. J. Neurochem. 72, 2053-2058.
18. Illenberger S., Zheng-Fischhofer Q., Preuss U. et al. (1998) The endogenous and cell cycle-dependent phosphorylation of tau protein in living cells: implications for Alzheimer's disease. Mol Biol. Cell 9, 1495-1512.
19. Ishiguro K., Sato K., Takamatsu M., Park J., Uchida T. and Imahori K. (1995) Analysis of phosphorylation of tau with antibodies specific for phosphorylation sites. Neurosci. Lett. 202, 81-84.
20. Ishizawa T., Sahara N., Ishiguro K., Kersh J., McGowan E., Lewis J., Hutton M., Dickson D. W. and Yen S.-H. (2003) Co-localzation of glycogen synthase kinase-3 with neurofibrillary tangles and granulovacuolar degeneration in transgenic mice. Am. J. Pathol. 163, 1057-1067.
21. Jicha G. A., Berenfeld B. and Davies P. (1999) Sequence requirements for formation of conformational variants of tau similar to those found in Alzheimer's disease. J. Neurosci. Res. 55, 713-723.
22. Kampers T., Friedhoff P., Biemat J., Mandelkow E. E. and Mandelkow E. (1996) RNA stimulates aggregation of microtubule-associated protein tau into Alzheimer-like paired helical filaments. FEBS Lett. 399, 344-349.
23. Kenessey A., Nacharaju P., Ko L. and Yen S.-H. (1997) Degradation of tau by lysosomal enzyme cathepsin D: implication for Alzheimer neurofibrillary degeneration. J. Neurochem. 69, 2026-2038.
24. Lee G., Newman S. T., Gard D. L., Band H. and Panchamoorthy G. (1998) Tau interacts with src-family non-receptor tyrosine kinases. J. Cell Sci. 111, 3167-3177.
25. Lee G., Thangavel R., Sharma V. M. et al. (2004) Phosphorylation of tau by Fyn: Implication for Alzheimer's disease. J. Neurosci. 24, 2304-2312.
26. Lee V. M., Goedert M. and Trojanowski J. Q. (2001) Neurodegenerative tauopathies. Ann. Rev. Neurosci. 24, 1121-1159.
27. Lewis J., McGowan E., Rockwood J. et al. (2000) Neurofibrillary tangles, amyotrophy and progressive motor disturbance in mice expressing mutant (P301L) tau protein. Nat. Genet. 25, 402-405.
28. Lewis J., Dickson D. W., Lin W. L. et al. (2001) Enhanced neurofibrillary degeneration in transgenic mice expressing mutant tau and APP. Science 293, 1487-1491.
29. Liu W. K., Williams R. T., Hall F. L., Dickson D. W. and Yen S.-H. (1995) Detection of a Cdc2-related kinase associated with Alzheimer paired helical filaments. Am. J. Pathol. 146, 228-238.
30. Noble W., Olm V., Takata K. et al. (2003) Cdk5 is a key factor in tau aggregation and tangle formation in vivo. Neuron 38, 555-565.
31. Pei J. J., Tanaka T., Tung Y. C., Braak E. and Iqbal K. and. Grundke-Iqbal I. (1997) Distribution, levels, and activity of glycogen synthase kinase-3 in the Alzheimer disease brain. J. Neuropathol. Ex., p. Neurol. 56, 70-78.
32. Pei J. J., Braak E., Braak H., Grundke-Iqbal I., Iqbal K., Winblad B. and Cowburn R. F. (1999) Distribution of active glycogen synthase kinase 3β (GSK-3β) in brains' staged for Alzheimer's disease neurofibrillary changes. J. Neuropathol. Exp. Neurol. 58, 1010-1019.
33. Pei J. J., Braak E., Braak H., Grundke-Iqbal I., Iqbal K., Winblad B. and Cowburn R. F. (2001) Localization of active forms of C-jun kinase (JNK) and p38 kinase in Alzheimer's disease brains at different stages of neurofibrillary degeneration. J. Alzheimer's Disease 3, 41-48.
34. Perez M., Valpuesta J. M., Medina M., Montejo de Garcini E. and Avila J. (1996) Polymerization of tau into filaments in the presence of heparin: the minimal sequence required for tau-tau interaction. J. Neurochem. 67, 1183-1190.
35. Planel E. and Sun X. and. Takashima A. (2002) Role of GSK-3β in Alzheimer's disease pathology. Drug Dev Res. 56, 491-510.
36. Reynolds C. H., Betts J. C., Blackstock W. P., Nebreda A. R. and Adnerton B. H. (2000) Phosphorylation sites on tau identified by nanoelectrospray mass sprectroscopy: differences in vitro between the mitogen-activated protein kinases ERK2, c-Jun N-terminal kinase and P38, and glycogen synthase kinase 3β. J. Neurochem. 74, 1587-1595.
37. Sahara N., Lewis J., DeTure M., McGowan E., Dickson D. W., Hutton M. and Yen S.-H. (2002) Assembly of tau in transgenic animals expressing P301L tau: alteration of phosphorylation and solubility. J. Neurochem. 83, 1498-1508.
38. Savage M. J., Lin Y. G., Ciallebella J. R., Flood D. G. and Scott R. W. (2002) Activation of c-Jun N-terminal kinase and p38 in an Alzheimer's disease model is associated with amyloid deposition. J. Neurosci. 22, 3376-3385.
39. Schneider A., Biernat J., von Bergen M., Mandelkow E. and Mandelkow E. M. (1999) Phosphorylation that detaches tau protein from microtubules (Ser262, Ser214) also protects it against aggregation into Alzheimer paired helical filaments. Biochemistry 38, 3549-3558.
40. Schwab C., DeMaggio A. J., Ghoshal N., Binder L. I., Kuret J. and McGeer P. L. (2000) Casein kinase I delta is associated with pathological accumulation of tau in several neurodegenerative diseases. Neurobiol. Aging 21, 503-510.
41. Sironi J. J., Yen S.-H., Gondal J. A., Wu O., Grundke-Iqbal I. and Iqbal K. (1998) Ser-262 in human recombinant tau protein is a markedly more favorable site for phosphorylation by CaMKII than PKA or PhK. FEBS Lett. 436, 471-475.
42. Sun A., Nguyen X. V. and Bing G. (2002) Comparative analysis of an improved thioflavin-S stain, Gallyas silver stain, and immunohistochemistry for neurofibrillary tangle demonstration on the same sections. J. Histochem. Cytochem. 50, 463-472.
43. Sun A., Liu M., Nguyen X. V. and Bing G. (2003) p38 MAP kinase is activated at early stages in Alzheimer's disease brain. Exp. Neurol. 183, 394-405.
44. Taniguchi T., Kawamata T., Mukai H. et al. (2001) Phosphorylation of tau is regulated by PKN. J. Biol. Chem. 276, 10025-10031.
45. Togo T., Sahara N., Yen S. H., Cookson N., Ishizawa T., Hutton M., de Silva R., Lees A. and Dickson D. W. (2002) Argyrophilic grain disease is a sporadic 4-repeat tauopathy. J. Neuropathol. Exp. Neurol. 61, 547-556.
46. Tomidokoro Y., Harigaya Y., Matsubara E. et al. (2001) Brain Aβ amyloidosis in APPsw mice induces accumulation of presenilin-1 and tau. J. Pathol. 194, 500-506.
47. Tortarolo M., Veglianese P., Calvaresi N., Botturi A., Rossi C., Giorgini A., Migheli A. and Bendotti C. (2003) Persistent activation of p38 mitogen-activated protein kinase in a mouse model of familial amyotrophic lateral sclerosis correlates with disease progression. Mol. Cell Neurosci. 23, 180-192.
48. Vincent I., Jicha G. and Rosado M. and. Dickson D. W. (1997) Aberrant expression of mitotic cdc2/cyclin B1 kinase in degenerating neurons of Alzheimer's disease brain. J. Neurosci. 17, 3588-3598.
49. Willamson R., Scales T., Clark B. R. et al. (2002) Rapid tyrosine phosphorylation of neuronal proteins including tau and focal adhesion kinase in response to amyloid-β peptide exposure: involvement of Src family protein kinases. J. Neurosci. 22, 10-20.
50. Wilson D. M. and Binder L. I. (1997) Free fatty acids stimulate the polymerization of tau and amyloid β peptides. In vitro evidence for a common effector of pathogenesis in Alzheimer's disease. Am. J. Pathol. 150, 2181-2195.
51. Yamaguchi H., Ishiguro K., Uchida T., Takashima A. and Lemere C. A. and. Imahori K. (1996) Preferential labeling of Alzheimer neurofibrillary tangles with antisera for tau protein kinase (TPK) I/glycogen synthase kinase-3β and cyclin-dependent kinase 5, a component of TPK II. Acta Neuropathol. 1, 232-241.
52. Yang S. D. Yu J. S., Shiah S. G. and Huang J. J. (1994) Protein kinase FA/glycogen synthase kinase-3 α after heparin potentiation phosphorylates tau on sites abnormally phosphorylated in Alzheimer's disease brain. J. Neurochem. 63, 1416-1425.
53. Yen S.-H., Crowe A. and Dickson D. W. (1985) Monoclonal antibodies to Alzheimer neurofibrillary tangles. 1. Identification of polypeptides. Am. J. Pathol. 120, 282-291.
54. Zhu X., Rottkamp C. A., Boux H., Takeda A., Perry G. and Smith M. A. (2000) Activation of p38 kinase links tau phosphorylation, oxidative stress, and cell cycle-related events in Alzheimer's disease. J. Neutopathol. Exp. Neurol. 59, 880-888.
55. Zhu X., Raina A. K., Rottkamp C. A., Aliev G., Perry G., Boux H. and Smith M. A. (2001) Activation and redistribution of c-jun N-terminal kinase/stress activated protein kinase in degenerating neurons in Alzheimer's disease. J. Neurochem. 76, 435-441.